Literature DB >> 8740650

Antisense oncogene and tumor suppressor gene therapy of cancer.

W W Zhang1.   

Abstract

Rapid advances in cancer gene therapy are driven by an explosive development of gene transfer technology and a strong demand for seeking alternatives to unsatisfactory conventional cancer therapies. Discovery of the genetic basis of cancer has indicated that cancer is a disease of genes. Among a variety of approaches to gene therapy of cancer, antisense oncogene and tumor suppressor gene therapy of cancer are the two strategies that aim at correcting genetic disorders of cancer through suppression of the abnormal expression of the proliferative genes. The potential effectiveness of these approaches is promised by their precise targeting at the mechanisms of the disease. Examples of several preclinical studies of these types of approaches that led to the approval of clinical trials are reviewed. Limitation and future development of these approaches are also discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740650     DOI: 10.1007/bf00204749

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  124 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

Authors:  T Mukhopadhyay; M Tainsky; A C Cavender; J A Roth
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

3.  Oligonucleotide therapeutics: a prospectus.

Authors:  S Crooke
Journal:  Antisense Res Dev       Date:  1993

4.  How tumour suppressor genes were discovered.

Authors:  H Harris
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

Review 5.  RNA as a catalyst: natural and designed ribozymes.

Authors:  U von Ahsen; R Schroeder
Journal:  Bioessays       Date:  1993-05       Impact factor: 4.345

Review 6.  Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53.

Authors:  M Montenarh
Journal:  Crit Rev Oncog       Date:  1992

7.  Tumor suppression by p21WAF1.

Authors:  Y Q Chen; S C Cipriano; J M Arenkiel; F R Miller
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.

Authors:  W W Zhang; X Fang; W Mazur; B A French; R N Georges; J A Roth
Journal:  Cancer Gene Ther       Date:  1994-03       Impact factor: 5.987

View more
  3 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth.

Authors:  Roger G Fahmy; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

3.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.